European Journal of Pain ncx 1236+ ncx139

European Journal of Pain Supplements
Volume 5, Issue 1, September 2011, Pages 180
Abstracts of Pain in Europe VII 7
doi:10.1016/S1754-3207(11)70618-6 | How to Cite or Link Using DOI
Permissions & Reprints

POSTER SESSION 2
F638 A NITRIC OXIDE (NO)-DONATING GABAPENTIN, NCX 1236, REVERSES THE DEVELOPMENT OF MECHANICAL ALLODYNIA IN STREPTOZOTOCIN-TREATED DIABETIC MICE

F.I. Impagnatiello, P.A. Borea, F. Vincenzi, M. Targa, V. Borghi, K. Varani
Purchase

Available online 25 October 2011.
-------------------------------------------------------------------------------------------------------------------------------------------------------------------
ncx 139

A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs Original Research Article
Experimental Eye Research, Volume 93, Issue 3, September 2011, Pages 243-249
F. Impagnatiello, V. Borghi, D.C. Gale, M. Batugo, M. Guzzetta, S. Brambilla, S.T. Carreiro, W.K.M. Chong, G. Prasanna, V. Chiroli, E. Ongini, A.H.P. Krauss

Highlights
► NCX 139 is a new chemical entity comprising latanoprost amide and a NO-donating moiety. ► NCX 139 but not its des-nitro analog resulted in selective NO-mediated vasorelaxant effect in pre-contracted rabbit aortic rings and 3H-PGF2α binding activity. ► NCX 139 significantly lowered IOP while the des-nitro analog was not effective (0.03% NCX 139, Δmax = −12.8 ± 2.0 mmHg) in transiently ocular hypertensive rabbits. ► In normotensive and glaucomatous dogs, NCX 139 decreased IOP to a greater extent compared to an equimolar dose of the respective des-nitro analog. ► Data support the concept that NCX 139 by targeting two different mechanisms, exerts potent ocular hypotensive effects in two different animal species.

Merci pour l'article mais peux-tu "traduire" moi qui ne suis pas expert ? A l'avance merci

NCX 139 successeur du ncx 116, visiblement.
Je ne le connaissais pas ce petit dernier.
Merci!